Giant cell myocarditis

详细信息    查看全文

• 作者：L.T. Cooper Jr. (1) cooper.leslie@mayo.edu
  C. ElAmm (2)
• 关键词：Myocarditis &#8211 ; Heart failure &#8211 ; Immunosuppression &#8211 ; Heart transplantation &#8211 ; Bridge to transplantation
• 刊名：Herz
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：37
• 期：6
• 页码：632-636
• 全文大小：464.9 KB
• 参考文献：1. Saltykow S (1905) Uber Diffuse Myokarditis Virchows Archiv fur Pathologische Anatomie 182:1–39
  2. Costanzo-Nordin M, Silver M, O’Connell J et al (1987) Giant cell myocarditis: dramatic hemodynamic histologic improvement with immunosuppressive therapy. Eur Heart Suppl J 271–274
  3. Davies M, Pomerance A, Teare R (1975) Idiopathic giant cell myocarditis—a distinctive clinico-pathological entity. Br Heart J 37:192–195
  4. Okura Y, Dec GW, Hare JM et al (2003) A clincal and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 41:322–328
  5. Kandolin R, Lehtonen J, Kupari M (2011) Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 4:303–309
  6. Cooper LT Jr, Berry GJ, Shabetai R (1997) Idiopathic giant-cell myocarditis—natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336:1860–1866
  7. Cooper L (2007) Giant cell myocarditis in children. Prog Pediatr Cardiol 24:47–49
  8. Cooper LT Jr, Hare JM, Tazelaar HD et al (2008) Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 102:1535–1539
  9. Vaideeswar P, Cooper L (2012) Giant cell myocarditis: clinical and pathological disease characteristics in an indian population. Cardiovascular Pathology (in press)
  10. Whitehead R (1965) Isolated myocarditis. Brit Heart J 27:220–230
  11. Okada R, Wakafuji S (1985) Myocarditis in autopsy. Heart Vessels Suppl 1:23–29
  12. Winters G, Costanzo-Nordin M (1991) Pathological findings in 2300 consecutive encomyocardial biopsies. Mod Pathol 441–448
  13. Kodama M, Matsumoto Y, Fujiwara M et al (1990) A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 57:250–262
  14. Hirono S, Islam MO, Nakazawa M et al (1997) Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. Circ Res 80:11–20
  15. Fuse K, Kodama M, Aizawa Y et al (2001) Th1/Th2 balance alteration in the clinical course of a patient with acute viral myocarditis. Jpn Circ J 65:1082–1084
  16. Chang H, Hanawa H, Yoshida T et al (2008) Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10-Ig fusion gene transfer. Circ J 72:813–819
  17. Asimaki A, Tandri H, Duffy ER et al (2011) Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 4:743–752
  18. Asimaki A, Tandri H, Huang H et al (2009) A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 360:1075–1084
  19. Kittleson M, Minhas K, Irizarry R et al (2005) Gene expression in giant cell myocarditis: Altered expression of immune response genes. Int J Cardiol 102:333–340
  20. Cooper L, Onuma O, Sagar S et al (2010) Genomic and proteomic analysis of myocarditis and dilated cardiomyopathy. Heart Fail Clinics North America 6:75–85
  21. Shields RC, Tazelaar HD, Berry GJ, Cooper LT Jr (2002) The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail 8:74–78
  22. Cooper LT, Baughman KL, Feldman AM et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116:2216–2233
  23. Mason JW, O’Connell JB, Herskowitz A et al (1995) A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 333:269–275
  24. Das B, Recto M, Johnsrude C et al (2006) Cardiac transplantation for pediatric giant cell myocarditis. J Heart Lung Transplant 25:474–478
  25. Cooper L, Orellana V, Schultheiss H-P et al (2012) Long term risk of death, transplantation, and disease recurrence in giant cell myocarditis. J Am Coll Cardiol 59:E1547 (Abstract)
  26. Brilakis E, Olson L, Berry G et al (2000) Survival outcomes of patients with giant cell myocarditis bridged to transplantation with ventricular assist devices. ASAIO J 46:569–572
  27. Murray LK, Gonz谩lez-Costello J, Jonas SN et al (2012) Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis. Eur J Heart Fail 14(3):312–318
  28. Scott R, Ratliff N, Starling R, Young J (2001) Recurrence of giant cell myocarditis in cardiac allograft. J Heart Lung Transplant 20:375–380
  29. Davies RA, Veinot JP, Smith S et al (2002) Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transplant 21:674–679
• 作者单位：1. Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, 55905 Rochester, MN, USA2. Division of Cardiovascular Diseases, University Hospitals of Cleveland, Cleveland, OH, USA
• ISSN：1615-6692

文摘

Giant cell myocarditis (GCM) usually presents as acute dilated cardiomyopathy that does not improve with guideline-based treatments. Ventricular tachycardia and heart block occur in a substantial number of patients. Diagnosis by endomyocardial biopsy can allow for the addition of immunosuppressive therapy and timely use of mechanical circulatory support when indicated. Recent studies suggest that the ventricular arrhythmias in GCM may be mediated by a cytokine-induced change in desmosomal protein expression. Genomic and proteomic studies suggest that the regulation of inflammatory pathways differs in GCM from lymphocytic myocarditis. Transplantation remains an effective therapy despite a 20–25% risk of GCM recurrence in the allograft. Recurrence in the native heart occurs up to 8 years after initial diagnosis. The long-term management of GCM patients, who initially recover, is not known and highlights the need for continuing multicenter collaborative clinical investigations.